$90.86
+0.52%
N/A+$0.47
보건의료
의료 - 유통
NASDAQ
활발히 거래 중
Henry Schein, Inc. (HSIC)는 포괄적인 의료 제품과 서비스를 제공하는 글로벌 리더입니다. 이 회사는 전 세계적으로 치과 전문가와 연구소, 의원(의사) 진료 현장, 정부 ...
Henry Schein, Inc. (HSIC)는 포괄적인 의료 제품과 서비스를 제공하는 글로벌 리더입니다. 이 회사는 전 세계적으로 치과 전문가와 연구소, 의원(의사) 진료 현장, 정부 ...
•Integration of new leadership vision
•Market competition in health care distribution
•Stable company structure and strong balance sheet
•Long-term trends in digital dental/medical health care
Frederick M. Lowery was appointed CEO in early 2026, succeeding long-time leader Stanley M. Bergman to spearhead the company's next phase of growth.
어린 시절: Lowery joined Henry Schein following a career in executive leadership, most recently serving in senior operational and strategic roles.
첫 기회: Appointment as CEO of Henry Schein, Inc. in March 2026 following an executive search process to find a successor for the 35-year veteran Stanley M. Bergman.
CEO가 되기까지: Lowery was selected by the board to modernize and scale the business, bringing external perspective to a company traditionally defined by its long-serving founder-like leader.
Frederick M. Lowery transitioned into the CEO role at Henry Schein in March 2026. His appointment marked the end of the 35-year tenure of Stanley M. Bergman, who transformed the company from a small distributor into a global Fortune 500 health care powerhouse. Lowery’s mandate is to build upon this legacy while adapting to the increasingly digital and complex landscape of global health care supply chain and technology solutions.
Frederick M. Lowery takes over a robust company with a dominant market position. The investment focus remains on his ability to drive growth through technological integration and operational efficiency while...
Lowery enters the CEO role after a career marked by senior executive operational roles.
이니셔티브: CEO
기간: 2026–Present
사건: Succeeding long-time leader Stanley M. Bergman.
Lowery has assumed leadership during a period of transition following decades of expansion under Bergman.
매출: Historically grew from $225M in 1989 to ~$13B under Bergman; Lowery is now focused on maintaining this scale.
수익성: Stable margin profile; transition focuses on margin expansion and technological integration.
주가: The stock is currently adjusting to the new leadership and strategic changes initiated in 2026.
Lowery is tasked with leading a complex, global organization through a modern operational refresh.
스타일: Strategic and operations-focused leader.
As the new CEO, Lowery is emphasizing organizational efficiency and the integration of technology into the company’s massive distribution network. His ability to lead a deeply ingrained corporate culture established by his predecessor is central to his early management strategy.
The company maintains a focus on disciplined capital allocation and strategic M&A.
Consistent focus on debt management and internal investment in core distribution capabilities.
The company continues its legacy of disciplined capital allocation, recently bolstered by strategic partnerships such as the 2025 KKR investment, which provided capital to support long-term value creation.
The company has a well-established credit profile and investor base.
Strategic equity investment · Not explicitly disclosed in snippet: KKR investment providing capital for future growth (2025)
희석: Moderate, with recent private equity involvement.
Investor confidence remains high due to the company's long-term financial track record and the orderly nature of the recent leadership handoff.
The company has maintained a professional governance structure with high board oversight.
복수의결권 주식: 아니오
주식 클래스 상세: Single-class share structure.
Governance is characterized by a strong, independent board. The transition of leadership included updates to board composition to ensure independent oversight following Bergman's retirement.
Succession is finalized, mitigating key-man risk associated with the previous CEO.
건강 상태: No public concerns.
승계 계획 공시: 예
핵심 인물 리스크: Low
Succession was successfully completed in 2026.
Technological innovation remains a key pillar of growth through the 'Henry Schein One' division.
Significant investment continues in digital dental platforms and software solutions.
Focuses on digitizing the dental and medical office workflow.
The R&D and technology strategy is heavily tied to the company's software and technology services, aiming to become the indispensable operating system for health care practitioners.
Talent retention and attraction are prioritized through a strong company culture.
High-quality, long-tenured leadership team remains in place.
유지율: Strong historical retention, now tested by leadership transition.
Maintaining the 'Team Schein' culture during the CEO transition is a core management priority to ensure key talent remains engaged.
Deep operational knowledge of the global health care supply chain.
Operational continuity: Leveraging a long-established, stable organizational foundation.
Lowery must prove his ability to replicate the growth achieved during the company's long initial expansion phase.
Transition risk
Managing the departure of a 35-year veteran leader.
예시: Ongoing post-succession execution.
Focuses on maintaining the brand's position as the world's largest provider of health care products and services.
High brand equity built over decades as a reliable partner to dental and medical practitioners.
The marketing strategy continues to center on 'Team Schein,' emphasizing partnership and community support for health care professionals, a brand pillar established during the Bergman era.
Lowery’s PR persona is currently being established as he takes on the public face of the company.
미디어 평판: Positive; media focus is currently on the orderly succession.
The succession has been communicated as a stable, long-planned transition. Lowery has stepped into a high-visibility role, with early public engagements focusing on stability and continuity.